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Yellow fever (YF) is a serious public health
problem in many tropical countries in Africa and
South America. In South America, most
infections are sporadic, affecting unvaccinated
persons who enter the forest; monkeys are the
primary reservoirs, and Haemagoggus sp. are
the vectors. French Guiana, located between
Brazil and Surinam in the Amazonian forest, has
had many epidemics of YF. However, no case has
been reported in French Guiana since 1902,
although a serologic survey in 1951 found
circulating virus; of 430 persons younger than 50
years of age (who had not been affected by the
1902 epidemic), 9% of those living in the coastal
area and 29% of those living inland had
significant titers of neutralizing YF antibodies
(1). A study conducted at the same time in
Surinam showed even higher rates of YF
seropositivity in persons who had not been
exposed to previous epidemics and confirmed
that YF viruses were circulating in the region
(2). In French Guiana, YF immunization became
compulsory in 1967.
Case Report
In March 1998, an Amerindian woman living
in a forest area on the Maroni River was
admitted to the health center in Maripasoula,
French Guiana, with fever, headache, abdominal
pain, vomiting, and diarrhea. She was treated for
malaria because of a Plasmodium falciparum
positive blood smear. Two days later, the
patients fever increased (40.2°C), she became
jaundiced, and she was evacuated to the
intensive care unit (ICU) at Cayenne Hospital
with multiple visceral failure: shock syndrome,
renal failure (blood urea level 32 mmol/l,
creatinine level 656 µmol/l), and liver failure
(total bilirubin level 314 µmol/l, alanine
aminotransferase 2048 IU/l, aspartate amino
transferase 6256 IU/l, prothrombin level 23%).
No hemorrhages were noted. Despite symptom-
atic treatment, the condition of the patient
deteriorated rapidly, and she died a few hours
after admission to ICU.
Blood cultures were negative for bacterial
pathogens. Because of anuria, urine cultures
were not possible, and albuminuria could not be
tested. Examination of peripheral blood smears
showed no parasites on admission to ICU and
titers of antibodies to leptospira were low.
Microscopy examination of postmortem liver
biopsies showed histopathologic changes charac-
teristic of YF: midzonal necrosis with a small rim
of a few viable periportal and pericentral
hepatocytes and centrilobular cells with
microsteatosis and eosinophilic degeneration
with round, eosinophilic cytoplasmic structures
(Councilman bodies).
A serum sample collected before death and a
serum sample obtained from the patient in 1994
during a seroepidemiologic study on HTLV-I
infection and stored at -80°C at the Institut
Pasteur de la Guyane, French Guiana, were
tested for immunoglobulin (Ig) G and IgM
specific for three flaviviruses (YF, dengue, and
Saint Louis encephalitis), two alphaviruses
Tonate and Mayaro), and a new world
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arenavirus (Tacaribe), by enzyme-linked
immunosorbent assay (3). A plaque reduction
neutralization test was also used to detect YF-
neutralizing antibodies (4). The serum collected
in 1998 contained IgM (but not IgG) that
specifically recognized YF antigens. IgM specific
for other flavivirus antigens (dengue, Saint
Louis encephalitis) were not found. The
neutralizing antibody titer of the 1998 serum as
assessed by plaque reduction neutralization test
was 20. In the serum collected in 1994, no YF
virusspecific antibodies were detected by any
technique. IgG to Mayaro virus was detected in
both sera; no other antibodies to alphaviruses
and arenaviruses were detected.
Serum and homogenized liver samples from
the patient were diluted 10-fold in Leibowitz
medium containing 3% fetal calf serum, and
dilutions were injected into subconfluent AP 61
cell cultures (5). After 7 days, cells were
harvested and tested for YF virus by an indirect
immunofluorescence assay using a monoclonal
antibody from the Centers for Disease Control
and Prevention, Fort Collins, CO, USA. YF virus
was not isolated by cell culture from either blood
or liver samples.
Reverse transcriptionpolymerase chain
reaction (RT-PCR) tests were performed on RNA
extracted from serum and liver (6). RNA of the
YF virus was detected by RT-PCR after
seminested PCR only in the liver sample. The
542-bp PCR product was purified and directly
sequenced with an automatic sequencing system
(ACTgene, EuroSequence Gene Services, Evry,
France). The first 309 nucleotides of the
3' noncoding sequence were aligned with those of
sequenced YF strains from Genbank (7,8).
Sequences were aligned with the Clustal W
program. Bootstrap confidence limits were
calculated from 100 replicates with the program
SEQBOOT. Phylogenetic analyses were per-
formed by maximum parsimony by using the
DNAPARS program with uniform character
weights and a heuristic search option. All branch
lengths were drawn to scale by the program
Treetool. The sequence of the YF strain isolated
in 1998 was deposited in Genbank (accession
number: AF121952).
The sequence of the amplified gene differed
at 11 positions (3.5% nucleotide divergence) from
that of a Brazilian strain isolated in 1935 and at
21 positions (6.8% nucleotide divergence) from
that of a strain isolated in Ecuador in 1979. The
sequence diverged more from strains isolated in
Peru (1995) and Trinidad (1979) (8.1% and 10%
divergence, respectively). As expected, African
strains differed more, with those of West Africa
(from Nigeria and Senegal) being less distant
than those from East and Central Africa
(Uganda and Central African Republic). The
nucleotide sequence downstream from the NS5
stop codon in the 3' noncoding region of the YF
virus was deleted in the French Guianese strain,
as in several South American YF viruses (9).
Phylogenetic analysis of the sequences con-
firmed that the virus was most closely related to
those isolated in Brazil and Ecuador (Figure).
Conclusions
The histopathologic changes of the liver were
characteristic of YF but also of other hemor-
rhagic fever viruses. The IgMs were only slightly
above the cut-off values used in the laboratory.
Although YF was highly probable, the diagnosis
required confirmation by detection of the virus or
its genome. Indeed, in 1990 a suspected case of
YF was reported to the World Health
Organization because of characteristic histo-
pathologic changes, but the case was never
confirmed (presence of IgG but no IgM specific
for YF, no detection of the virus in liver or
serum); later it was shown that the patient had
been vaccinated against YF 1 year before (10).
However, because YF requires health authori-
ties to take specific measures, confirmation of the
diagnosis is important, especially when YF is not
prevalent. The case we described was confirmed
by RT-PCR from liver only, because the serum
sample was taken on day 6 when viremia is
usually resolved and because the sensitivity of
cell culture for virus in liver samples is very low
(probably because of biliary salts toxicity). This
case underscores the need for postmortem liver
biopsies for detecting the viral genome to
confirm diagnosis.
This patient did not leave her village the
months before infection; she was probably
infected while working in forest clearings. The
detection of a YF virus in French Guiana nearly
a century after the last report is notable;
however, the absence of reported cases during
the previous years is surprising because no
natural borders exist between this country and
northern Brazil, where YF is not uncommon (11).
A severe YF outbreak would have easily been
detected, but sporadic cases can be misdiagnosed431 Vol. 5, No. 3, MayJune 1999 Emerging Infectious Diseases
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Figure. Phylogenetic tree generated from 309
nucleotides of the 3' noncoding region of the strain of
yellow fever (YF) isolated in French Guiana in 1998
(in bold) and of 14 other YF strains by using the
DNAPARS program. Numbers indicate bootstrap
values for groups to the right. One µl (30 ng) of primer
VD8 (5'-GGGTCTCCTCTAACCTCTAG-3') was mixed
with RNA resuspended in 10 µl of distilled water; the
mixture was heated at 95°C for 2 minutes and placed
on ice. cDNA was synthesized in a mixture containing
reverse transcriptase (RT) incubation buffer (pro-
vided by the manufacturer), 0.2 mM of each of the
four dNTPs, 20 units RNasine, and five units of AMV
RT (Promega, Charbonnières, France) by incubation
for 1 hour at 42°C. cDNA was amplified by PCR. Four
µl of the cDNA sample was added to 46 µl of a mixture
containing Taq polymerase buffer (provided by the
manufacturer), 2 mM MgCl2, 0.5 mM of each of
the 4 dNTPs, 300 ng of primer VD8 and of degenerate
primer EMF1 (5'-TGGATGACSACKGARGAYATG-3')
(S = C, G; K = G, T; R = A, G; Y = C, T), and 0.5 unit
of Taq polymerase (Promega, Charbonnières,
France). After 5 minutes of denaturation at 95°C, the
mixture was subjected to 30 polymerase chain
reaction (PCR) cycles: 95°C for 30 seconds, 53°C for 90
seconds, and 72°C for 60 seconds, followed by a final
10-minute polymerization step at 72°C. Four µl of a 1
in 100 dilution of the PCR products was used for
seminested PCR using primers VD8 and NS5YF
(5'-ATGCAGGACAAGACAATGGT-3'). After the de-
naturation step, DNA was amplified by 25 cycles of
PCR: 94°C for 30 seconds, 55°C for 90 seconds, and
72°C for 120 seconds, followed by a final extension
step at 72°C. Negative controls (serum from healthy
persons) were included in the series. The positive
control (supernatant of infected mosquito cells) was
tested separately to avoid any contamination. The
phylogenetic analysis was conducted by the Pasteur
Institute in Paris.
as other fevers or as hepatitis (when jaundice is
present) and may be not tested for YF even
though serologic and YF virus detection tests are
performed for each suspected case.
No other case was diagnosed in the patients
family or neighborhood, but sporadic cases are
common in South America (12), probably because
of poorly anthropophilic vectors. Furthermore,
in this area, approximately 90% of the population
have been vaccinated at least once (R. Pignoux,
unpub. data). Outbreaks are common among
nonhuman primates, but no epidemic has
occurred in the area where the patient lived.
However, YF incidence increased in northern
Brazil in 1998 (13).
This case calls attention to vaccination
problems in French Guiana, especially along the
rivers. Our patient had been vaccinated in 1985,
but the absence of neutralizing antibodies in
1994 indicates that the vaccination was not
effective. Although this patient may have had a
poor antibody response, more likely inadequate
storage of the vaccine before use was responsible.
In 1985, YF vaccines were less thermostable
than now, and the cold chain was difficult to
maintain. In response to this case, an
immunization campaign was initiated in this
area in May.
Vaccination of the population must continue
since YF can reappear. The immunization
program implemented in French Guiana
(compulsory vaccination of children older than
1 year of age, booster YF vaccination every 10
years, and required vaccination certificate before
entering school) should avert the threat of
outbreaks in urban areas, which have a vaccine
coverage rate of approximately 80%. However,
the risk for sporadic cases in unvaccinated
persons will persist, and so active serologic and
virologic surveillance of YF remains necessary.
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